Meningitis, Cryptococcal clinical trials
The registry lists 54 studies for Meningitis, Cryptococcal across more than 10 countries. 6 are recruiting or about to start. 50 of them are mainly about Meningitis, Cryptococcal (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09.
Get an email when these change. Save the Meningitis, Cryptococcal studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Pfizer (11) · National Institute of Allergy and Infectious Diseases (NIAID) (8) · University of Minnesota (5) · National Hospital for Tropical Diseases, Hanoi, Vietnam (3) · University of Zimbabwe (2) · ANRS, Emerging Infectious Diseases (2) · Matinas BioPharma Nanotechnologies, Inc. (2) · Novartis Pharmaceuticals (2)
What is being tested here
Drugs under test in Meningitis, Cryptococcal studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The study
- Jun 2027Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia · Phase 3 · Makerere University
Who these studies take
Of the 4 Meningitis, Cryptococcal studies recruiting now, 3 (75%) set no upper age limit and 0 (0%) stop at 75 or younger. 1 (25%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (50%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 4 (100%) | 4 (100%) |
| 30 | 4 (100%) | 4 (100%) |
| 40 | 4 (100%) | 4 (100%) |
| 50 | 4 (100%) | 4 (100%) |
| 65 | 4 (100%) | 4 (100%) |
| 75 | 4 (100%) | 4 (100%) |
| 85 | 4 (100%) | 4 (100%) |
Across all 54 studies, recruiting or not: 4% stop at 75 or younger and 2% at 65; 33% take children; 0% are for women only and 0% for men only; 7% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 50 of 54. Browse all 54 → or search them.
- Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ LymphocytopeniaRecruitingNCT008672691 country
- Fungal Infection SusceptibilityRecruitingNCT000013521 country
- Optimizing Care for Cryptococcal Antigenemia: Evaluation of Short Course Fluconazole and ART Timing Among CrAg+ Persons With Low TitersNot yet recruitingNCT07743593Phase 31 country
- Platform Trial For Cryptococcal Meningitis (PLATFORM-CM)RecruitingNCT06666322Phase 2/31 country
- Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal AntigenemiaRecruitingNCT03945448Phase 2/31 country
- Amphotericin B for Non-HIV Cryptococcal Meningitis PatientsEnrolling by invitationNCT06178627Phase 41 country
- Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal MeningitisCompletedNCT06414512Phase 21 country
- Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT)CompletedNCT04031833Phase 1/21 country
- Point of Care Tests to Identify Opportunistic Infections in Advanced HIV Patients in Mexico CityStatus unknownNCT05685641Not applicable1 country
- Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3Status unknownNCT05541107Phase 3
- Clinical Study of ABCD in the Treatment of Cryptococcal MeningitisStatus unknownNCT05471063Not applicable1 country
- Driving Reduced AIDS-associated Meningo-encephalitis MortalityCompletedNCT03226379Not applicable3 countries
- Clinical Effectiveness and Safety of Amphotericin B With Flucytosine-Fluconazole Therapy for Cryptococcal MeningitisCompletedNCT045324631 country
- The Lived Experience of Participants in an African Randomised TrialCompletedNCT042962923 countries
- High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected IndividualsCompletedNCT00885703Phase 1/28 countries
- A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal MeningitisCompletedNCT00000639Not applicable1 country
- Dexamethasone in Cryptococcal MeningitisCompletedNCT00000776Phase 22 countries
- Three Induction Treatments on Cryptococcal MeningitisStatus unknownNCT04072640Early Phase 11 country
- Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal MeningitisCompletedNCT01802385Phase 31 country
- Cryptococcal Optimal ART Timing TrialCompletedNCT01075152Phase 42 countries
- Operational Research for Cryptococcal Antigen ScreeningCompletedNCT01535469Phase 41 country
- Treatment With Tamoxifen in Cryptococcal MeningitisCompletedNCT03112031Phase 21 country
- AmB Dose for Cryptococcal MeningitisStatus unknownNCT04140461Phase 31 country
- CryptoART Study: Decreasing Mortality Associated With Initiation of Antiretroviral Therapy in Sub-Saharan AfricaCompletedNCT024341721 country
- Vietnam Cryptococcal Retention in Care Study (CRICS) Federal Financial ReportCompletedNCT02955862Phase 11 country
- Pre-Antiretroviral Therapy (ART) Cryptococcal Antigen Screening in AIDSStatus unknownNCT02624453Not applicable1 country
- Vietnam Cryptococcal Retention in Care Study Version 1.0Status unknownNCT023346701 country
- Vietnam Cryptococcal Retention in Care Study - Version 2.1Status unknownNCT032674071 country
- Early Versus Delayed Antiretroviral Therapy (ART) in the Treatment of Cryptococcal Meningitis in AfricaCompletedNCT00830856Not applicable1 country
- Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Sub-saharan AfricaStatus unknownNCT01715922Phase 2/32 countries
- Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal MeningitisStatus unknownNCT02686853Phase 4
- Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases in Neurological Disorders in DRCCompletedNCT01589289Phase 31 country
- Liposomal Amphotericin B for the Treatment of Cryptococcal MeningitisStatus unknownNCT02136030Not applicable1 country
- Clinical Outcomes of Cryptococcal Meningitis Among HIV-infected Patients in the Era of Antiretroviral TherapyCompletedNCT020985251 country
- Amphotericin Alone or in Combination With Fluconazole for AIDS-Associated MeningitisCompletedNCT00145249Phase 22 countries
- Optimal Time to Start Antiretroviral Therapy in HIV-infected Adults With Cryptococcal MeningitisCompletedNCT00976040Phase 41 country
- Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal MeningitisCompletedNCT00000708Not applicable1 country
- Comparison of Fluconazole and Amphotericin B in the Treatment of Brain Infections in Patients With AIDSCompletedNCT00001017Phase 31 country
- Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal MeningitisCompletedNCT00012467Phase 22 countries
- Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDSTerminatedNCT00847678Phase 21 country
- Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDSTerminatedNCT00324025Phase 21 country
- A Study of Fluconazole in the Treatment of Cryptococcal Meningitis in Patients Who Have Not Had Success With Amphotericin BCompletedNCT00002306Not applicable1 country
- A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis.CompletedNCT00002113Not applicable1 country
- Safety and Efficacy of Amphotericin B Lipid Complex in the Treatment of Cryptococcal Meningitis in Patients With the Acquired Immunodeficiency SyndromeCompletedNCT00002019Not applicable1 country
- The Safety and Effectiveness of RMP-7 Plus Amphotericin B in Patients With HIV and Cryptococcal MeningitisCompletedNCT00002316Phase 11 country
- Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal MeningitisCompletedNCT00002040Not applicable1 country
- A Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal MeningitisCompletedNCT00002068Not applicable2 countries
- A Study of Fluconazole in the Treatment of Cryptococcal Meningitis in Patients With AIDSCompletedNCT00002294Not applicable1 country
- Pilot Study of Oral Fluconazole in the Treatment of Acute Cryptococcal MeningitisCompletedNCT00002076Not applicable1 country
- Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Maintenance Treatment for the Prevention of Relapse of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency SyndromeCompletedNCT00002074Not applicable2 countries